SCHEDULE 13D/A: Helix Acquisition Corp. II Announces Definitive Business Combination with BridgeBio Oncology Therapeutics, Securing $260M PIPE Investment

Helix Acquisition Corp. II has entered into a definitive business combination agreement with BridgeBio Oncology Therapeutics, Inc., which includes a $260 million PIPE investment and a planned domestication to Delaware.

Summary

• Helix Acquisition Corp. II (Helix) has entered into a definitive Business Combination Agreement with TheRas, Inc. (doing business as BridgeBio Oncology Therapeutics, Inc. 'BBOT').
• The transaction involves Helix de-registering from the Cayman Islands and domesticating to Delaware, becoming 'BridgeBio Oncology Therapeutics, Inc.' (PubCo), followed by a merger where BBOT becomes a wholly-owned subsidiary of PubCo.
• The aggregate merger consideration to be issued to BBOT stockholders is determined by dividing an Equity Value of $461,051,546 by the Redemption Price of Helix's Class A ordinary shares.
• In connection with the merger, Helix will redeem public shares, the Sponsor will forfeit a portion of its Class B ordinary shares (Sponsor Forfeited Shares), and remaining Class B shares will convert to Class A shares on a one-for-one basis.
• Certain shareholders and insiders, including the Sponsor and Cormorant-affiliated funds, have entered into a Support Agreement, committing to vote in favor of the Business Combination and agreeing not to redeem their Class A shares.
• The Sponsor has agreed to forfeit additional PubCo Common Stock if Helix Closing Cash is less than $400,000,000, based on a specific formula.
• Helix has secured approximately $260,000,000 in PIPE (Private Investment in Public Equity) investments from qualified institutional buyers and accredited investors, with Cormorant Asset Management, LP subscribing for $75,000,000.
• Post-closing, key shareholders, including the Sponsor and Cormorant-affiliated funds, will be subject to a one-year lock-up period on their PubCo Common Stock.
• PubCo will also enter into an Amended and Restated Registration Rights Agreement, committing to file a resale registration statement for certain shares within 30 calendar days of the Closing Date.

Sentiment

Score: 8

Explanation: The announcement of a definitive business combination, coupled with a significant PIPE investment and strong shareholder support, indicates a positive step forward for the company. While there are forfeiture conditions for the Sponsor, the overall sentiment is positive due to the clarity and progress towards a merger.

Positives

• Securing a definitive business combination agreement provides clarity on the SPAC's path forward.
• The $260,000,000 PIPE investment demonstrates investor confidence and provides significant capital for the combined entity.
• Cormorant's substantial $75,000,000 PIPE commitment indicates strong backing from a key investor.
• The support agreements from major shareholders ensure voting in favor of the transaction and commitment not to redeem shares, increasing the likelihood of successful closing.
• The domestication to Delaware and name change to 'BridgeBio Oncology Therapeutics, Inc.' aligns the corporate structure and identity with the operating business.

Negatives

• The Sponsor is required to forfeit a portion of its Class B ordinary shares (Sponsor Forfeited Shares) prior to domestication, which could reduce their ownership stake.
• An additional forfeiture of PubCo Common Stock by the Sponsor is contingent on Helix Closing Cash being less than $400,000,000, introducing a potential downside for the Sponsor.
• Existing Class B shareholders waive their rights to a conversion ratio greater than one-to-one, potentially foregoing a more favorable conversion.
• The one-year lock-up agreement for key shareholders restricts their ability to sell shares post-merger, potentially limiting liquidity for those parties.

Risks

• Consummation of the Business Combination is subject to approval by stockholders of both BBOT and Helix.
• The Business Combination is contingent on the satisfaction or waiver of other conditions stated in the Business Combination Agreement.
• The Sponsor's forfeiture of PubCo Common Stock is tied to the Helix Closing Cash, meaning if cash falls below $400,000,000, the Sponsor's stake will be reduced.
• The success of the combined entity, BridgeBio Oncology Therapeutics, Inc., will depend on its ability to execute its business plan in the highly competitive oncology therapeutics industry.

Future Outlook

Upon the closing of the Business Combination, Helix Acquisition Corp. II will de-register from the Cayman Islands, domesticate as a Delaware corporation, and change its name to 'BridgeBio Oncology Therapeutics, Inc.' The combined entity will then merge with TheRas, Inc. (BBOT), making BBOT a wholly-owned subsidiary. The consummation of the Business Combination is subject to stockholder approvals and other customary closing conditions.

Industry Context

This announcement reflects the ongoing trend of Special Purpose Acquisition Companies (SPACs) seeking to complete business combinations, particularly within the biotechnology and healthcare sectors. The merger with BridgeBio Oncology Therapeutics, Inc. positions the combined entity within the competitive oncology therapeutics market, a high-growth area driven by significant R&D and unmet medical needs. The substantial PIPE investment indicates continued investor appetite for promising biotech ventures, even within the SPAC structure.

Management Changes

Corporate Governance

Related Party Transactions

• Transfer of 30,000 Class B ordinary shares from Sponsor (Helix Holdings II LLC) to Albert A. Holman III, an independent director.
• Cormorant Asset Management, LP, an affiliate of the Reporting Persons, subscribed for $75,000,000 in the PIPE Investments.
• Sponsor, Fund III, Fund V, Master Fund, and other investment vehicles of Cormorant (affiliates controlled by Ms. Chen) are parties to the Helix Support Agreement, Lock-Up Agreement, and A&R Registration Rights Agreement.

Stakeholder Impact

• Shareholders: Existing Class A shareholders will see their shares convert to PubCo Common Stock. Public shareholders have redemption rights. Class B shareholders will convert to Class A one-for-one, with the Sponsor forfeiting some shares. All shareholders will be subject to the terms of the Business Combination.
• Employees: BBOT employees will become employees of a wholly-owned subsidiary of PubCo, with their stock options converting to PubCo options.
• Investors (PIPE): New investors will acquire PubCo Common Stock, providing capital to the combined entity.
• Management/Directors: New board composition for PubCo, with Sponsor designating two members. An independent director received shares as an inducement.

Next Steps

• Helix will de-register in the Cayman Islands and transfer by way of continuation into the State of Delaware (Domestication).
• Helix will change its name to 'BridgeBio Oncology Therapeutics, Inc.' (PubCo) upon Domestication.
• Merger Sub will merge with and into BBOT, making BBOT a wholly-owned subsidiary of PubCo.
• Stockholders of both BBOT and Helix must approve the Business Combination.
• Satisfaction or waiver of conditions stated in the Business Combination Agreement.
• PubCo will file a registration statement with the SEC within 30 calendar days following the Closing Date to register the resale of certain shares.

Key Dates

Recommendation

Keywords

Helix Acquisition Corp. II, BridgeBio Oncology Therapeutics, BBOT, SPAC, Business Combination, Merger, PIPE Investment, SEC Filing, Schedule 13D, Beneficial Ownership, Cormorant Asset Management, Biotechnology, Oncology, Delaware Domestication, Share Forfeiture, Lock-Up Agreement, Registration Rights